Effect of Cinnamaldehyde on Systemic Candida albicans Infection in Mice.
10.1007/s11655-023-3754-5
- Author:
Xiao-Ru GUO
1
;
Xiao-Guang ZHANG
2
;
Gang-Sheng WANG
3
;
Jia WANG
4
;
Xiao-Jun LIU
5
;
Jie-Hua DENG
6
,
7
Author Information
1. Department of Infectious Diseases, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
2. Department of Dermatovenereology, Clinical Research Center for Dermatovenereology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
3. The Second Hospital of Hebei Medical University, Quanbo Pharmaceuticals, Shijiazhuang, 050000, China.
4. Research Office, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
5. Department of Hematology, Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
6. Department of Dermatovenereology, Clinical Research Center for Dermatovenereology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China. djh092@
7. com.
- Publication Type:Journal Article
- Keywords:
(1,3)-β-D-glucan detection;
cinnamaldehyde;
fungal examination;
systemic Candida albicans infection
- MeSH:
Animals;
Acrolein/pharmacology*;
Candida albicans/physiology*;
Mice, Inbred BALB C;
Candidiasis/pathology*;
Antifungal Agents/therapeutic use*;
Mice;
Fluconazole/therapeutic use*;
Kidney/drug effects*;
Female
- From:
Chinese journal of integrative medicine
2025;31(7):644-648
- CountryChina
- Language:English
-
Abstract:
OBJECTIVE:To investigate the therapeutic efficacy of cinnamaldehyde (CA) on systemic Candida albicans infection in mice and to provide supportive data for the development of novel antifungal drugs.
METHODS:Ninety BALB/c mice were randomly divided into 3 groups according to a random number table: CA treatment group, fluconazole (positive control) group, and Tween saline (negative control) group, with 30 mice in each group. Initially, all groups of mice received consecutive intraperitoneal injections of cyclophosphamide at 200 mg/kg for 2 days, followed by intraperitoneal injection of 0.25 mL C. albicans fungal suspension (concentration of 1.0 × 107 CFU/mL) on the 4th day, to establish an immunosuppressed systemic Candida albicans infection animal model. Subsequently, the mice were orally administered CA, fluconazole and Tween saline, at 240, 240 mg/kg and 0.25 mL/kg respectively for 14 days. After a 48-h discontinuation of treatment, the liver, small intestine, and kidney tissues of mice were collected for fungal direct microscopic examination, culture, and histopathological examination. Additionally, renal tissues from each group of mice were collected for (1,3)- β -D-glucan detection. The survival status of mice in all groups was monitored for 14 days of drug administration.
RESULTS:The CA group exhibited a fungal clearance rate of C. albicans above 86.7% (26/30), significantly higher than the fluconazole group (60.0%, 18/30, P<0.01) and the Tween saline group (30.0%, 9/30, P<0.01). Furthermore, histopathological examination in the CA group revealed the disappearance of inflammatory cells and near-normal restoration of tissue structure. The (1,3)-β-D-glucan detection value in the CA group (860.55 ± 126.73 pg/mL) was significantly lower than that in the fluconazole group (1985.13 ± 203.56 pg/mL, P<0.01) and the Tween saline group (5910.20 ± 320.56 pg/mL, P<0.01). The mouse survival rate reached 90.0% (27/30), higher than the fluconazole group (60.0%, 18/30) and the Tween saline group (30.0%, 9/30), with a significant difference between the two groups (both P<0.01).
CONCLUSIONS:CA treatment exhibited significant therapeutic efficacy in mice with systemic C. albicans infection. Therefore, CA holds potential as a novel antifungal agent for targeted treatment of C. albicans infection.
